Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thymoma × lenvatinib × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 19 Carcinoma, Renal Cell 13 Parkinson Disease 4, Autosomal Dominant Lewy Body 12 Endometrial Neoplasms 9 Thyroid Neoplasms 4 Neoplasms 4 Liver Neoplasms 4 Biliary Tract Neoplasms 4 Uterine Cervical Neoplasms 3 Neuroendocrine Tumors 3 Cholangiocarcinoma 3 Carcinoma, Non-Small-Cell Lung 3 Thyroid Carcinoma, Anaplastic 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Colorectal Neoplasms 2 Clear-cell metastatic renal cell carcinoma 2 Carcinoma, Transitional Cell 2 Adenocarcinoma 2 von Hippel-Lindau Disease 1 Vulvar Neoplasms 1 Triple Negative Breast Neoplasms 1 Thymoma 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Sarcoma, Kaposi 1

Interventions

pembrolizumab 3 Cyclophosphamide 2 olaparib 1 lenvatinib 1 fludarabine 1 avelumab 1 Sunitinib 1 Magnetic Resonance Spectroscopy 1 Doxorubicin 1 Cisplatin 1 Chemoradiotherapy 1 Carboplatin 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04710628 2026-02-19

PECATI

MedSIR

Phase 2 Completed

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡